Can Exercise Boost Your Flu Shot? What a Systematic Review of Trials and Observational Studies Really Shows

Table of Contents

1. Key Highlights
2. Introduction
3. What the review examined: scope, methods and outcomes
4. How exercise interventions were categorized and compared
5. What the randomized trials show about acute exercise and antibody responses
6. Chronic training and habitual fitness: imprecise and inconsistent effects
7. Hemagglutination inhibition titers: what they mean and what they don’t
8. Biological plausibility: how exercise could influence vaccine responses
9. Why the evidence remains inconclusive: methodological constraints and heterogeneity
10. Practical implications for clinicians, vaccine recipients and public health
11. Real-world examples and scenarios
12. What stronger evidence would look like
13. Where future research should focus
14. Limitations of the review itself
15. Final interpretive summary
16. FAQ

Key Highlights

• A systematic review of 22 reports found no definitive randomized evidence that a single bout of exercise or regular training reliably increases antibody responses to influenza vaccination; certainty of evidence was low to very low.
• Meta-analyses of randomized trials showed no clear effect of acute exercise on seroprotection or seroconversion for H1N1 and H3N2 strains; chronic-training estimates were imprecise and inconsistent across influenza A and B strains.
• Observational associations between habitual activity or fitness and vaccine antibody levels are vulnerable to confounding; larger, better-reported randomized trials with clinical endpoints are needed before exercise can be recommended as an immunologic adjuvant to influenza vaccines.

Introduction

Each year public health campaigns urge vaccination to reduce influenza burden. The immune response to seasonal influenza vaccines, however, varies between people. That variability has prompted investigation into behavioral strategies that might improve vaccine-induced immunity. Exercise—both a single, pre-vaccination bout and longer-term training—stands out as a plausible, low-cost candidate. Short bursts of activity mobilize immune cells and shift cytokine milieus; sustained physical activity improves cardiorespiratory fitness and reduces chronic inflammation. These biological effects create a credible mechanism by which exercise could influence vaccine responses.

Researchers have tested that hypothesis in small trials and observational studies for decades. Individual reports produced mixed results. The systematic review and meta-analysis examined here pooled available evidence to determine whether acute exercise, chronic training, or habitual activity and fitness measures consistently affect humoral responses to influenza vaccination in adults. The review analyzed randomized trials separately from nonrandomized interventions and observational data, applied standard risk-of-bias instruments and GRADE certainty ratings, and restricted immunogenicity outcomes to hemagglutination inhibition (HAI) antibody measures commonly used in influenza vaccine research.

The findings clarify what the available data do—and do not—show. They also expose substantial gaps that must be filled before recommending exercise as an adjuvant strategy to improve flu vaccine efficacy.

What the review examined: scope, methods and outcomes

The authors searched six major databases from inception through May 1, 2026, and identified 22 eligible reports. They included randomized trials of acute exercise (single sessions performed around the time of vaccination) and chronic-training interventions (structured exercise programs delivered over weeks). Nonrandomized interventions and observational studies of habitual physical activity or measured fitness were analyzed separately.

The focus was on humoral immune responses measured by hemagglutination inhibition (HAI) assays. Key outcomes included:

• Seroprotection: proportion of participants achieving an HAI titer at or above a threshold considered protective (commonly ≥1:40).
• Seroconversion: proportion showing a four-fold rise in HAI titer from baseline.
• Quantitative titer changes: mean differences in log2-transformed HAI titers.

Randomized evidence provided the primary quantitative estimates. When trials were sufficiently compatible, meta-analyses pooled risk ratios (RRs) for binary outcomes and mean differences (MDs) for continuous titer measures. The review used design-appropriate tools for assessing risk of bias and applied GRADE to rate certainty of evidence.

Registration of the systematic review occurred in PROSPERO (CRD420261425732), and the authors classified overall certainty as low or very low for the primary comparisons.

How exercise interventions were categorized and compared

The review treated exercise interventions in three distinct categories, reflecting different biological expectations and study designs:

• Acute exercise: Single sessions, often performed immediately before vaccination, designed to generate transient physiological changes (e.g., increased circulation, leukocyte mobilization, stress hormone release). Acute interventions in the included trials ranged in mode and intensity but typically involved aerobic or resistance exercise performed on the day of vaccination.
• Chronic training: Supervised or prescribed exercise programs spanning weeks to months, intended to induce longer-term adaptations such as improved cardiorespiratory fitness, reductions in resting inflammation, and altered metabolic profiles. Chronic-training trials measured antibody responses after the training period and vaccination schedule.
• Observational measures of habitual activity and physical fitness: Cross-sectional or cohort-style comparisons using self-reported physical activity questionnaires or objective fitness metrics (e.g., VO2max). These studies assessed associations of habitual behaviors or fitness with post-vaccination HAI responses.

The authors separated randomized and nonrandomized evidence to avoid conflating trial-level causality with associations prone to confounding.

What the randomized trials show about acute exercise and antibody responses

Meta-analyses of randomized trials did not provide clear evidence that a single exercise session around vaccination meaningfully alters HAI-based seroprotection or seroconversion.

Key pooled estimates:

• H1N1 seroprotection: RR 0.88 (95% CI 0.65–1.21; k = 3 trials). This estimate crosses the line of no effect and the confidence interval includes values compatible with both harm and benefit.
• H3N2 seroprotection: RR 1.04 (95% CI 0.91–1.20; k = 3). The point estimate is near unity, and the CI is narrow enough to suggest no large effects but remains compatible with modest benefit or harm.
• H1N1 seroconversion: RR 1.30 (95% CI 0.58–2.92; k = 2). Precision is poor; the CI is wide.
• H3N2 seroconversion: RR 0.84 (95% CI 0.50–1.40; k = 2). Again, the interval spans benefit and harm.

Five randomized reports contributed to at least one meta-analysis of two or more trials; other randomized comparisons were supported by single trials only. The authors judged overall certainty low to very low, primarily because of small sample sizes, risk of bias in several trials, and imprecision.

Interpretation: The randomized data do not establish that a single exercise session reliably improves hemagglutination inhibition antibody responses to influenza vaccination. The pooled estimates do not demonstrate clear harm, but neither do they confirm benefit. In plain terms, existing randomized trials are too few and too small to draw firm conclusions about acute exercise as an adjuvant.

Chronic training and habitual fitness: imprecise and inconsistent effects

Two randomized trials contributed pooled continuous titer estimates after chronic-training interventions. Results were imprecise and did not point to consistent improvements across influenza strains.

Pooled mean differences (log2 HAI titers) for chronic training versus control:

• H1N1: MD 0.50 log2 units (95% CI −0.64 to 1.64; k = 2). CI includes both meaningful benefit and no effect.
• H3N2: MD 0.27 (95% CI −0.17 to 0.72; k = 2). Small, imprecise effect.
• Influenza B: MD −0.14 (95% CI −0.64 to 0.36; k = 2). Point estimate suggests no benefit.

Observational associations between habitual physical activity or higher measured fitness and antibody responses appeared more promising in some reports. Those studies typically found higher titers or greater odds of seroconversion among more active or fitter individuals. However, the review highlights that such associations are vulnerable to confounding. People who maintain higher activity levels also tend to differ in age, comorbid conditions, socioeconomic status, nutrition, sleep, and healthcare behaviors. Those factors themselves influence immune function and vaccine response.

The randomized chronic-training evidence does not establish a clinically meaningful improvement in HAI antibody responses. It remains possible that specific populations or particular training modalities yield benefit, but current trials provide inadequate precision to confirm such subgroup effects.

Hemagglutination inhibition titers: what they mean and what they don’t

Understanding the review’s outcomes requires a brief primer on HAI assays and immunogenicity endpoints commonly used in vaccine studies.

• Hemagglutination inhibition (HAI) titer: A measure of antibodies that block virus-induced agglutination of red blood cells. HAI titers correlate imperfectly with protection against clinical influenza. Researchers often log2-transform titers for analysis, which makes titer increases interpretable as doubling steps.
• Seroprotection: Often defined as an HAI titer of 1:40 or greater. This threshold emerged from population-level correlations with reduced influenza risk but does not guarantee individual protection. It is a surrogate marker, not a direct clinical endpoint.
• Seroconversion: Typically defined as a four-fold rise in HAI titer from baseline, indicating a robust antibody response to vaccination.

HAI measures are useful for comparing immunogenicity between vaccine formulations or interventions within trials. They remain surrogate markers. The review’s authors explicitly note that antibody findings do not establish effects on clinical influenza illness, hospitalization, or transmission. Demonstrating reduced incidence of laboratory-confirmed influenza requires adequately powered trials with clinical endpoints or vaccine effectiveness studies.

Biological plausibility: how exercise could influence vaccine responses

Exercise influences immune function through several immediate and long-term mechanisms that provide biological plausibility for a potential effect on vaccine-induced antibody responses.

Acute mechanisms triggered by a single exercise session:

• Leukocyte mobilization: Exercise causes transient increases in circulating neutrophils, monocytes, and lymphocytes, potentially enhancing antigen presentation and immune surveillance at the time of vaccination.
• Stress hormone changes: Exercise elevates catecholamines and cortisol, which can modulate immune cell trafficking and function. Short-term catecholamine surges may enhance lymphocyte homing to lymphoid tissue, whereas cortisol can dampen inflammation. Timing, intensity, and mode of exercise likely influence net effects.
• Local inflammation and blood flow: Muscle contraction increases local blood flow and cytokine release (myokines), which could influence antigen uptake or local immune cell recruitment at the injection site.

Chronic mechanisms with regular training:

• Improved cardiorespiratory fitness and metabolic health reduce chronic inflammation, which in theory could restore more robust adaptive immune responses in individuals with baseline immunosenescence or chronic inflammatory states.
• Enhanced vaccine responsiveness through better overall health, sleep quality, and nutritional status often associated with regular physical activity.

These mechanisms make the hypothesis plausible. Yet plausibility alone does not replace rigorous randomized evidence demonstrating consistent immunologic benefit.

Why the evidence remains inconclusive: methodological constraints and heterogeneity

Several recurring limitations in the existing literature explain why the systematic review reached cautious, low-certainty conclusions.

Small sample sizes and imprecision Many randomized trials enrolled tens, not hundreds, of participants. Small samples inflate uncertainty around effect estimates; CIs remain wide and include both clinically important benefit and harm. Few trials contributed to pooled analyses for the same strain and outcome, limiting statistical power.

Heterogeneity of interventions Studies differed in critical ways:

• Acute protocols varied in mode (aerobic vs resistance), intensity (moderate vs vigorous), duration, and timing relative to vaccination.
• Chronic programs ranged from low-frequency home-based regimens to supervised aerobic training.
• Participants differed by age, baseline activity and fitness, comorbidity burden, and prior vaccine history.

Outcome heterogeneity Investigators reported different immunogenicity outcomes and at varying time points. Some reported binary seroprotection/seroconversion, others quantitative titer changes, and follow-up timing ranged from weeks to months. That variability limited opportunities for pooling and interpretation.

Incomplete or inconsistent numerical reporting Some trials reported outcomes only graphically or failed to provide key summary statistics needed for meta-analysis. Incomplete reporting obstructs synthesis and inflates risk of selective reporting bias.

Risk of bias and study conduct Design-appropriate risk-of-bias tools identified concerns in several trials. Issues included lack of blinding (difficult in exercise interventions), incomplete outcome data, and potential deviations from intended interventions.

Observational confounding Studies of habitual activity or fitness cannot rule out residual confounding. Active people differ in many health-related behaviors and socio-demographics that affect vaccine responses. Adjustment strategies in observational studies varied and often could not account for unmeasured confounders.

Strain- and vaccine-specific factors Immunogenicity varies by vaccine strain and formulation. Studies spanned multiple influenza seasons and vaccine compositions; strain-specific effects further complicate pooling and generalization.

Taken together, these constraints make it impossible to declare a reliable immunogenicity benefit from acute or chronic exercise based on current randomized data.

Practical implications for clinicians, vaccine recipients and public health

The review provides clear guidance for interpreting current evidence and informing practice.

Do not recommend exercise primarily as a vaccine adjuvant Given the low certainty and imprecision of randomized evidence, clinicians should not advise patients to exercise immediately before or after influenza vaccination with the specific aim of improving antibody responses. Existing data do not demonstrate consistent benefit, and the trials are insufficient to rule out meaningful effects in either direction.

Encourage exercise for overall health and established benefits Physical activity remains one of the most important behaviors for preventing chronic disease, improving mental health, and enhancing quality of life. Patients should continue to follow national guidelines for activity (e.g., accumulating moderate-to-vigorous activity across the week and incorporating strength training). Those recommendations rest on extensive evidence separate from vaccine immunogenicity.

Vaccination timing and logistics should not be disrupted Clinical workflows and vaccination campaigns should not be modified solely to accommodate exercise interventions intended to boost immunogenicity. Public health efforts should prioritize vaccination access, uptake, and the use of vaccines matched to circulating strains.

Special populations: older adults and immunocompromised patients Older adults exhibit immunosenescence and often have reduced vaccine responses. Theoretically, they could benefit from interventions that modulate immune function. The current randomized evidence does not support routine exercise prescriptions specifically aimed at improving antibody responses in older adults. However, regular physical activity remains an important strategy to maintain functional independence and reduce disease risk in this population.

Interpreting antibody measures clinically Even modest increases in HAI titers may not translate to meaningful reductions in clinical influenza incidence. Trials assessing vaccine effectiveness require sufficient size and clinical endpoints. Until such data exist, patients and clinicians should not equate small immunogenicity differences with proven increases in protection.

Real-world examples and scenarios

Illustrative examples help translate the review’s findings into practical judgments.

Example 1: The weekend warrior who plans a pre-vaccine workout A 35-year-old office worker plans a vigorous spin class immediately before getting a flu shot, hoping to boost antibody response. The randomized evidence does not show consistent benefit for such an acute exercise strategy. While a single vigorous session will not likely harm the vaccine response, it is not a proven way to increase protection. The person should be reassured that vaccination remains the primary protective measure.

Example 2: The older adult beginning a training program before flu season A 68-year-old with controlled hypertension starts a 12-week walking program to improve health and hopes it will increase vaccine effectiveness. Chronic-training trials have produced imprecise titer estimates. While improved fitness has many proven health advantages, current evidence does not reliably show that short-term training before vaccination augments antibody responses. The training remains advisable for general health but should not replace vaccination or other preventive measures.

Example 3: Public health clinic considering exercise stations at vaccine sites A community health clinic contemplates offering brief exercise sessions before vaccination to increase immunogenicity and attract participants. Given the current evidence, such a policy is unlikely to meaningfully change immunogenicity at the population level. Clinic resources should focus on proven strategies: improving vaccine access, offering education about vaccine benefits, and providing appropriate vaccine formulations for older adults or high-risk groups.

These scenarios highlight that exercise is valuable for broad health outcomes, yet should not be positioned as a reliable method to improve flu vaccine antibody responses based on current trial evidence.

What stronger evidence would look like

The review identifies specific design features and reporting practices that would strengthen future evidence:

• Larger randomized trials: Sample sizes powered to detect clinically meaningful differences in seroconversion or seroprotection, and ideally powered for clinical endpoints such as laboratory-confirmed influenza.
• Standardized intervention protocols: Clear, replicable descriptions of exercise modality, intensity, duration and timing relative to vaccination to permit comparisons across trials.
• Uniform immunogenicity reporting: Agreement on reporting HAI geometric mean titers, seroconversion rates, seroprotection proportions, and use of consistent time points post-vaccination (e.g., 4 weeks). Complete numerical reporting should accompany graphical presentations.
• Appropriate blinding and allocation concealment where feasible: While participant blinding is difficult for behavioral interventions, outcome assessors and laboratory personnel can be blinded to allocation.
• Rigorous control for confounding in nonrandomized studies: Use of robust analytic methods (propensity scores, instrumental variables) and careful measurement of potential confounders when randomized trials are not possible.
• Clinical endpoints: Trials that include laboratory-confirmed influenza, physician visits for influenza-like illness, or hospitalization to determine whether immunologic differences translate to clinical benefit.
• Stratified analyses: Evaluation of specific subgroups (older adults, people with chronic conditions, prior vaccine history) to detect populations that might derive differential benefit.

Adoption of these features would reduce uncertainty and help determine whether exercise can be a bona fide immunologic adjuvant.

Where future research should focus

The biological plausibility and suggestive observational findings justify targeted trials rather than broad abandonment of the hypothesis.

Priority areas:

• Mechanistic trials with immunophenotyping: Small mechanistic studies can map how exercise alters antigen presentation, B cell activation, germinal-center dynamics, and memory responses. Such studies can refine hypotheses about timing, intensity, and exercise modality.
• Trials in older adults: Age-related immune decline makes older adults a high-priority group. Well-powered trials in this population could detect clinically meaningful benefits if present.
• Mode and timing optimization: Comparative trials that randomize participants to resistance versus aerobic exercise, and to different timings (immediately before vs hours before vaccination) would clarify which protocols, if any, are most promising.
• Clinical effectiveness trials: Ultimately, trials must examine whether exercise-based strategies reduce laboratory-confirmed influenza, severity, or healthcare utilization. Immunologic surrogates cannot substitute for clinical outcomes when determining public health recommendations.
• Integration with vaccine innovation: Research could test whether exercise enhances responses to adjuvanted vaccines or high-dose formulations used in older adults, as interactions between vaccine formulation and host physiology may matter.

Researchers must prioritize transparent, complete reporting and pre-registration of protocols to facilitate synthesis and reproducibility.

Limitations of the review itself

The systematic review applied robust methods, but limitations merit acknowledgment.

• Publication date cutoff: The search extended to May 1, 2026. Any trials published after that date are not included.
• Dependence on available data: The review could only synthesize what primary reports provided. Incomplete reporting limited meta-analysis scope.
• Heterogeneity constraining pooling: Differences in interventions and populations restricted meta-analytic comparisons to subsets of trials.

Despite these constraints, the review offers the most comprehensive synthesis to date of randomized and observational evidence linking exercise and influenza vaccine humoral responses.

Final interpretive summary

Randomized evidence to date does not establish that a single session of exercise around the time of influenza vaccination or a short-term training program reliably improves antibody responses measured by HAI. Observational associations between habitual activity or fitness and higher antibody levels are suggestive but remain susceptible to confounding. The totality of evidence carries low to very low certainty for the primary comparisons.

Exercise remains a cornerstone of healthy living and warrants encouragement for broad health benefits. Using exercise solely to enhance influenza vaccine immunogenicity is not supported by current randomized data. Researchers should conduct larger, better-reported randomized trials—ideally with clinical endpoints—to determine whether any exercise protocols reliably augment vaccine protection in specific populations.

FAQ

Q: Should I exercise just before or after receiving my flu shot to increase its effectiveness?
A: Current randomized trials do not show consistent benefit for a single bout of exercise performed around the time of vaccination. Exercise immediately before or after vaccination is unlikely to harm the vaccine response for most people, but it should not be done with the primary expectation of improving antibody responses.

Q: Does being physically fit make the flu vaccine work better?
A: Observational studies often find associations between higher fitness or greater habitual activity and stronger antibody responses. Those associations may reflect healthier baseline characteristics among active people rather than a causal effect of fitness itself. Randomized trials of training programs have produced imprecise results that do not confirm a reliable benefit.

Q: Are there specific groups who might benefit from exercise as an adjuvant?
A: Older adults and people with chronic inflammatory conditions are biologically plausible targets because they often have reduced vaccine responses. However, current randomized evidence does not confirm that exercise improves antibody responses in these groups. Focused, adequately powered trials are needed.

Q: What types of exercise have been tested in the trials?
A: Trials have evaluated both aerobic and resistance exercise in acute protocols and a range of supervised or prescribed chronic training programs. Heterogeneity in mode, intensity, duration, and timing reduces the ability to identify one superior approach from existing data.

Q: Do changes in hemagglutination inhibition titers translate to real-world protection?
A: HAI titers are surrogate markers correlated with protection at the population level but do not guarantee individual protection. Trials showing immunogenicity differences need confirmation by clinical endpoints—laboratory-confirmed influenza or reduced healthcare utilization—before being used to guide public health practice.

Q: Will more research likely change recommendations?
A: Possibly. Larger randomized trials with standardized protocols and clinical endpoints could detect clinically meaningful effects if they exist. Until such data appear, exercise should be promoted for its many proven health benefits, not as a validated vaccine adjuvant.

Q: Is it safe to exercise after vaccination?
A: For most people, light to moderate exercise after vaccination is safe. Participants who experience acute systemic reactions (fever, significant malaise) should rest until symptoms resolve. There is no evidence from the trials reviewed that routine post-vaccination activity causes harm to vaccine responses.

Q: What should clinicians tell patients who ask whether to time exercise around their flu shot?
A: Clinicians should emphasize that vaccination is the primary means of influenza prevention. They should encourage regular physical activity for general health but avoid promoting exercise timing as a proven method to improve vaccine-induced immunity based on current evidence.

Q: How can policymakers or clinics use this information?
A: Clinics should prioritize proven measures: increasing vaccine access, ensuring appropriate vaccine formulations for high-risk groups, and public education. Allocating resources to exercise programs solely to enhance vaccine immunogenicity is premature without stronger randomized evidence.

Q: Where can interested readers find the detailed review?
A: The systematic review was registered in PROSPERO (CRD420261425732) and includes pooled estimates for H1N1, H3N2, and influenza B strains, along with GRADE certainty assessments. The review’s full text contains the methodology and trial-level details used to reach these conclusions.